ERBB2 and cancer: ZW49, composed of zanidatamab + disulfide bond linker + tubulin inhibitor auristatin, is another bsADC that has entered the clinical stage (Phase I) for patients with HER2-positive cancers; however, the clinical data did not meet expectations, and most patients experienced treatment-related adverse events.